Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO 2025 GU Cancer Highlights
Featuring presentations & discussions on selected GU abstracts from the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
Chair: Neeraj Agarwal | Moderators: Andrea Necchi & Elizabeth Plimack
Session 1: Latest in novel treatments, combinations and long-term outcomes in RCC and bladder cancer
Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA
Thomas Powles Barts Cancer Institute, London, United Kingdom
Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC)
Naomi Haas University of Pennsylvania, Pennsylvania, PA, United States
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma
Alexandra Drakaki University of California, Los Angeles, CA, CA, United States
Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study
Michael Harrison Duke Cancer Institute, Durham, NC, United States
Panel discussion
Investigating outcomes, evolving therapeutics & biomarkers in prostate cancer
Exploratory analyses of homologous recombination repair alterations (HRRm) by gene subgroup and potential associations with efficacy in the HRR-deficient population from TALAPRO-2
Stefanie Zschaebitz Zschaebitz Heidelberg University, Heidelberg , Germany
Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC)
Capucine Baldini Gustave Roussy Institute, Villejuif, France
Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE
Nicholas James University College London Cancer Institute , London, United Kingdom
Panel discussion
